Organization (Academic)
Dokuz Eylül University
ClinicalTrials.gov lists Dokuz Eylül University as lead sponsor of 254 trials, counting the companies grouped under it. Dokuz Eylül University itself has 30 active development programs and 9 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 14 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 17 in 2026 and about 23 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
This page covers Dokuz Eylül University and 1 company grouped under it: 254 lead-sponsored trials (253 its own, 1 in the grouped companies) and 2 legal-entity registrations (1 its own, 1 in the grouped companies).
Companies grouped under this page (1)
| Company | Lead trials | Legal entities |
|---|---|---|
| Izmir Biomedicine and Genome Center | 1 | 1 |
Disease areas (188)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Pain | 40 |
| Anxiety Disorders | 28 |
| Multiple Sclerosis | 17 |
| Acute Pain | 10 |
| Neck Pain | 9 |
Showing 5 of 188 disease areas.
Trials by start year as sponsor or collaborator (19)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 14 |
| 2025 | 27 |
| 2024 | 24 |
| 2023 | 39 |
| 2022 | 50 |
| 2021 | 32 |
| 2020 | 15 |
| 2019 | 26 |
| 2018 | 21 |
| 2017 | 22 |
Showing 10 of 19 years.
Prediction, not a registry value: median of 28 months from start to primary completion across 15 trials still running at the 2026-10-09 snapshot; 3 of 15 predicted trials reach the 36-month horizon; registered median of 9 months across 179 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (30)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Exercise | Peripheral Arterial Disease | Not reported | 1 |
| Low Level Laser Therapy | Tendinopathy | Not reported | 1 |
| Low Level Laser Therapy | Trigger Finger Disorder | Not reported | 1 |
| Exercise | Atherosclerosis | Not reported | 1 |
| Quadro iliac Plane Block | Osteoarthritis | Not reported | 1 |
Showing 5 of 30 active programs.
Approved assets (9)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Remi 0.3 | 1 |
| Remi 0.1 | 1 |
| Remi 0.2 | 1 |
| MOMETASONE FUROATE | 1 |
| Voriconazole | 2 |
Showing 5 of 9 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 74% hit target (n=80) | 49% on time (n=76) |
Journals published in (264)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Cochrane database of systematic reviews | 11 |
| Archives of physical medicine and rehabilitation | 10 |
| Journal of clinical periodontology | 9 |
| Best practice & research. Clinical anaesthesiology | 6 |
| Gynecologic oncology | 6 |
Showing 5 of 264 journals.
Organization relationships (172)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Izmir Katip Celebi University | Co sponsors trial with | 5 |
| Marmara University | Co sponsors trial with | 3 |
| Necmettin Erbakan University | Co sponsors trial with | 3 |
| Trakya University | Co sponsors trial with | 3 |
| Pamukkale University | Co sponsors trial with | 3 |
Showing 5 of 172 relationships.
Latest dated events (305)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-11-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-10-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-09-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 305 events.
Biomarker capability evidence (43)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| DMD | Trial sponsor | Named in trial inclusion criteria |
| HADH | Trial sponsor | Named in trial inclusion criteria |
| HYLS1 | Trial sponsor | Named in trial inclusion criteria |
| MAFIP | Trial sponsor | Named in trial inclusion criteria |
| MAFIP | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 43 evidence rows.
Biomarkers this organization publishes on (109)
Shown in this order: most publications first.
Showing 5 of 109 biomarkers.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.